Theradaptive moves OsteoAdapt SP into pivotal FDA-backed trial

Theradaptive said the U.S. Food and Drug Administration has cleared it to start the pivotal Phase 3 portion of its OASIS trial for OsteoAdapt SP, an investigational regenerative therapy for spinal fusion. The study is evaluating OsteoAdapt SP as an alternative to autologous and allograft bone graft in single-level TLIF, ALIF, and LLIF procedures for symptomatic degenerative disease of the lumbosacral spine. The company said the program builds on earlier clinical experience in about 100 participants and follows a December 2024 FDA decision that expanded its Phase I/II IDE study to include all three lumbar fusion approaches. (prnewswire.com)

Why it matters: For veterinary professionals, this is a human spine story, but it’s relevant because it reflects continued investment in orthobiologics designed to improve bone healing while reducing the tradeoffs tied to graft harvesting and conventional BMP-2 use. Theradaptive says OsteoAdapt SP uses AMP2, an engineered BMP-2 variant intended to stay localized on a synthetic graft and limit off-target bone growth and inflammation, issues that have shaped the broader conversation around bone regeneration products. That kind of platform work can influence how clinicians and industry think about future regenerative approaches across orthopedics, including translational research that may eventually inform animal health. (prnewswire.com)

What to watch: Next comes pivotal-trial enrollment, execution across sites, and, if results are supportive, a path toward FDA premarket approval. (prnewswire.com)